Lung perfusion solution, and use thereof for the ex-vivo preservation of a mammalian lung

Abstract

A lung perfusion solution comprises a base solution comprising a physiological mixture of electrolytes and buffers, 3.5-5.5% (w/v) a first macromolecule having a molecular weight of 40-100 KDa, and an amount of a second, high molecular weight, macromolecule sufficient to adjust the relative viscosity of the solution to 2.0-3.0.

1 . An organ perfusion solution comprising: a base solution comprising a physiological mixture of electrolytes and buffers; and 3.5-5.5% (w/v) a first macromolecule having a molecular weight of 40-100 kDa, characterised in that the solution comprises an amount of a second, high molecular weight, macromolecule sufficient to adjust the relative viscosity of the solution to 2.0-3.0. 
     
     
         2 . An organ perfusion solution of  claim 1 , in which the solution comprises an amount of a second, high molecular weight, macromolecule sufficient to adjust the relative viscosity of the solution to about 2.5. 
     
     
         3 . An organ perfusion solution of  claim 1 , in which the solution comprises an amount of a second, high molecular weight, macromolecule sufficient to adjust the relative viscosity of the solution to about 2.5 and in which the second, high molecular weight, macromolecule has a molecular weight of 350-450 kDa. 
     
     
         4 . An organ perfusion solution of  claim 1 , in which the second, high molecular weight, macromolecule is a branched polysaccharide-based polymer. 
     
     
         5 . An organ perfusion solution of  claim 1 , in which the second, high molecular weight, macromolecule is non-ionic. 
     
     
         6 . An organ perfusion solution of  claim 1 , in which the second, high molecular weight, macromolecule is a FICOLL PM400. 
     
     
         7 . An organ perfusion solution of  claim 1 , in which the second, high molecular weight, macromolecule is provided in an amount of 2-5% (w/v). 
     
     
         8 . An organ perfusion solution of  claim 1 , in which the first macromolecule is a molecule having a molecular weight of 60-80 KDa. 
     
     
         9 . An organ perfusion solution of  claim 1 , in which the first macromolecule is a polysaccharide-based polymer. 
     
     
         10 . An organ perfusion solution of  claim 1 , in which the first macromolecule is non-ionic. 
     
     
         11 . An organ perfusion solution of  claim 1 , in which the high molecular weight macromolecule is a FICOLL PM70. 
     
     
         12 . An organ perfusion solution of  claim 1 , in which the first macromolecule is provided in an amount of 3-5% (w/v). 
     
     
         13 . An organ perfusion solution of  claim 1 , and comprising:
 3-5% of the first macromolecule, in which the first macromolecule has a molecular weight of 60-80 KDa; 2-5% of the second macromolecule, in which the second macromolecule has a molecular weight of 350-600 KDa.   
     
     
         14 . An organ perfusion solution of  claim 1 , and comprising 3-5% of the first macromolecule, in which the first macromolecule has a molecular weight of 60-80 KDa; 2-5% of the second macromolecule, in which the second macromolecule has a molecular weight of 350-600 KDa, and in which the first and second macromolecules are polysaccharide-based polymers. 
     
     
         15 . An organ perfusion solution of  claim 1 , in which the organ is selected from a lung, a heart, a kidney and a liver. 
     
     
         16 . A method of perfusing an organ ex vivo comprising a step of perfusing an organ perfusion solution of  claim 1 , through the organ. 
     
     
         17 .- 31 . (canceled) 
     
     
         32 . An organ perfusion solution  claim 15 , in which the organ is a lung.